natgillin/translations-raw huggingface dataset:
Vials of Dectova are for single use only. 
Bočice lijeka Dectova namijenjene su samo za jednokratnu uporabu.
The pharmacokinetics in elderly subjects was similar to young adult subjects. 
Farmakokinetika u starijih ispitanika bila je slična onoj u mladih odraslih ispitanika.
Table 6: Statistical comparisons of TTCR between the 600 mg zanamivir group and each other group (IPP) 
Tablica 6: Statističke usporedbe TTCR-a između skupine koja je primala 600 mg zanamivira i svake od ostalih skupina (IPP)
The primary endpoint was time to clinical response (TTCR); clinical response was defined as a composite of vital sign stabilisation (temperature, oxygen saturation, respiratory status, heart rate and systolic blood pressure) or hospital discharge. 
Primarna mjera ishoda bilo je vrijeme do kliničkog odgovora (engl. time to clinical response, TTCR), koji se definirao kao stabilizacija vitalnih znakova (temperature, zasićenosti kisikom, respiratornog statusa, srčanog ritma i sistoličkog krvnog tlaka) ili otpuštanje iz bolnice.
• being less alert or not responding to loud sounds or being shaken 
• smanjena razina budnosti ili izostanak reakcije na glasne zvukove ili protresanje
There are limited data from the use of zanamivir in pregnant women. 
Postoje ograničeni podaci o primjeni zanamivira u trudnica.
Treatment with Dectova should commence as soon as possible and usually within 6 days of the onset of symptoms of influenza (see section 5.1). 
Liječenje lijekom Dectova treba započeti što je prije moguće, obično unutar 6 dana od nastupa simptoma gripe (vidjeti dio 5.1).
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, or toxicity to reproduction and development, with the exception of a rat embryofoetal development study (subcutaneous administration). 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenog potencijala te reproduktivne i razvojne toksičnosti, uz izuzetak ispitivanja učinaka na embriofetalni razvoj u štakora
Dectova should not be administered simultaneously with other intravenous medicinal products or prepared in solutions containing glucose or other electrolytes (see section 6.6). 
Dectova se ne smije primjenjivati istodobno s drugim lijekovima za intravensku primjenu niti pripremati u otopinama koje sadrže glukozu ili druge elektrolite (vidjeti dio 6.6).
• Use aseptic techniques throughout preparation of the dose. 
• Tijekom cijelog postupka pripreme doze mora se koristiti aseptična tehnika.
Pharmacotherapeutic group: Antivirals for systemic use, neuraminidase inhibitors ATC code: J05AH01 
Farmakoterapijska skupina: Antivirotici za sistemsku primjenu, inhibitori neuraminidaze ATK oznaka: J05AH01
During treatment with Dectova, changes in behaviour such as confusion and unresponsiveness may occur. 
Tijekom liječenja lijekom Dectova moguće su promjene u ponašanju, kao što su smetenost i izostanak reakcije na podražaje.
• Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. 
• kada drugi antivirusni lijekovi za liječenje gripe, uključujući zanamivir za inhalacijsku primjenu, nisu prikladni za određenog bolesnika.
The European Medicines Agency has deferred the obligation to submit the results of studies with Dectova in one or more subsets of the paediatric population in the treatment and prevention of influenza (see section 4.2 for information on paediatric use). 
Pedijatrijska populacija Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Dectova u jednoj ili više podskupina pedijatrijske populacije za liječenje i prevenciju gripe (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
The plasma protein binding of zanamivir is very low (less than 10%). 
Zanamivir se u vrlo maloj mjeri vezuje za proteine u plazmi (manje od 10%).
Psychiatric disorders abnormal behaviour hallucinations delirium not known 
Psihijatrijski poremećaji neuobičajeno ponašanje halucinacije delirij nepoznato
• The patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or 
• kada se zna ili sumnja da je virus gripe kojim je bolesnik zaražen otporan na druge lijekove protiv gripe osim zanamivira, i/ili
Pharmacokinetic studies in Thai, Chinese and Japanese healthy subjects did not identify any clinically relevant differences in the pharmacokinetics of zanamivir in these populations compared with Caucasians. 
Farmakokinetička ispitivanja provedena u tajlandskih, kineskih i japanskih zdravih ispitanika nisu ukazala ni na kakve klinički značajne razlike u farmakokinetici zanamivira u tim populacijama u odnosu na bijelce.
What you need to know before you are given Dectova 
Što morate znati prije nego počnete primati lijek Dectova
In the population pharmacokinetic analysis, age had no significant effect on the pharmacokinetics of zanamivir. 
Prema populacijskoj farmakokinetičkoj analizi, dob nije značajno utjecala na farmakokinetiku zanamivira.
For patients receiving continuous renal replacement therapy, the dose should be selected using the appropriate CRRT clearance (CLCRRT in mL/min). 
Za bolesnike koji primaju kontinuiranu bubrežnu nadomjesnu terapiju dozu treba odabrati na temelju odgovarajućeg CRRT klirensa (CLCRRT u ml/min).
There is limited experience of overdose from administration of Dectova. 
Postoji ograničeno iskustvo s predoziranjem kod primjene lijeka Dectova.
Annual reports to be submitted 
Obvezno je podnositi godišnja izvješća
The amount you are given is based on your age, body weight, and the results of your blood tests (to check how well your kidneys are working). 
Vašoj dobi, tjelesnoj težini i nalazima krvnih pretraga (kojima se provjerava koliko Vam dobro rade bubrezi).
If you have any questions on the use of Dectova, ask the doctor or nurse who is giving it you. 
U slučaju bilo kakvih pitanja u vezi s primjenom lijeka Dectova, obratite se liječniku ili medicinskoj sestri koja Vam ga daje.
Dectova has no or negligible influence on the ability to drive and use machines. 
Dectova ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Resistance selection during zanamivir treatment is rare. 
Selekcija rezistentnih sojeva virusa tijekom liječenja zanamivirom je rijetka.
Elderly No dose adjustment is required based on age. 
Nije potrebno prilagođavati dozu na temelju dobi.
Zanamivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells and promotes virus spread in the respiratory tract. 
Zanamivir je inhibitor neuraminidaze virusa gripe, enzima koji oslobađa virusne čestice iz plazmatske membrane zaraženih stanica i pospješuje širenje virusa u dišnom sustavu.
In adults with normal renal function, the elimination half-life is approximately 2-3 hours. 
Poluvrijeme eliminacije u odraslih s normalnom bubrežnom funkcijom iznosi približno 2 - 3 sata.
• severe allergic reactions, including features such as itchy rash, swelling of the face, throat or tongue, breathing difficulty, light headedness and vomiting. 
• teške alergijske reakcije, uključujući značajke kao što su osip koji svrbi, oticanje lica, grla ili jezika, otežano disanje, ošamućenost i povraćanje Česte nuspojave
As experience is limited, the use of zanamivir in breast-feeding mothers should be considered only if the possible benefit to the mother is thought to outweigh any possible risk to the child. 
S obzirom na ograničeno iskustvo, primjenu zanamivira u dojilja treba razmotriti samo ako se smatra da moguća korist za majku nadmašuje sve moguće rizike za dijete.
There are limited data on zanamivir exposure during concomitant continuous renal replacement therapy and very limited data with dialysis. 
Postoje ograničeni podaci o izloženosti zanamiviru tijekom istodobne kontinuirane bubrežne nadomjesne terapije i vrlo ograničeni podaci o primjeni kod dijalize.
• serum zanamivir levels from patients with complicated influenza (see section 5.1). 
• podataka o serumskim razinama zanamivira u bolesnika s kompliciranom gripom (vidjeti dio 5.1)
As experience is limited, the use of Dectova in pregnancy should only be considered if the possible benefit to the patient is thought to outweigh any possible risk to the foetus. 
S obzirom na ograničeno iskustvo, primjenu lijeka Dectova u trudnica treba razmotriti samo ako se smatra da moguća korist za bolesnicu nadmašuje sve moguće rizike za plod.
Hepatic impairment No dose modification is required (see section 5.2). 
Nije potrebno prilagođavati dozu (vidjeti dio 5.2).
This medicine contains 70.8 mg sodium (main component of cooking/table salt) in each vial. 
Ovaj lijek sadrži 70,8 mg natrija (glavnog sastojka kuhinjske soli) u jednoj bočici.
Any unused solution should be discarded. 
Sva neupotrijebljena otopina mora se baciti.
 6 years to < 18 years 
≥ 6 godina do < 18 godina
Zanamivir had a significant prophylactic effect against an experimental challenge with influenza A virus as demonstrated by the low infection rate (14% vs. 100% positive serology in placebo group, p <0.005), isolation of virus by viral culture (0% vs. 100% in placebo group, p <0.005), as well as reductions in fever (14% vs. 88% in placebo group, p <0.05), upper respiratory tract illness (0% versus 100% in placebo group, p<0.005) and total symptom scores (1 vs. 44 median score in placebo group, p<0.001). 
Zanamivir je pokazao značajan profilaktički učinak pri eksperimentalnom izlaganju virusu gripe tipa A, što je dokazano niskom stopom infekcije (pozitivan serološki nalaz: 14% naspram 100% u skupini koja je primala placebo, p < 0,005) i izolacije virusa iz virusne kulture (0% naspram 100% u skupini koja je primala placebo, p < 0,005), kao i smanjenjem stope vrućice (14% naspram 88% u skupini koja je primala placebo, p < 0,05) i bolesti gornjih dišnih putova (0% naspram 100% u skupini koja je primala placebo, p < 0,005) te ukupnih rezultata za simptome (medijan rezultata: 1 naspram 44 u skupini koja je primala placebo, p < 0,001).
For patients on intermittent haemodialysis or intermittent peritoneal dialysis, the dose should be given after completion of the dialysis session. 
U bolesnika koji su na intermitentnoj dijalizi ili intermitentnoj peritonejskoj dijalizi dozu treba primijeniti nakon završetka postupka dijalize.
The clinical impact of reduced susceptibility in these viruses is unknown, and the effects of specific substitutions on virus susceptibility to zanamivir may be strain-dependent. 
Klinički značaj smanjene osjetljivosti tih virusa nije poznat, a učinci specifičnih supstitucija na osjetljivost virusa na zanamivir mogli bi biti ovisni o soju.
The H275Y substitution is the most common neuraminidase resistance substitution and is associated with reduced susceptibility to peramivir and oseltamivir. 
Supstitucija H275Y najčešća je supstitucija neuraminidaze koja uzrokuje rezistenciju, a povezana je sa smanjenom osjetljivošću na peramivir i oseltamivir.
Reduced susceptibility to zanamivir is associated with mutations that result in amino acid changes in the viral neuraminidase or viral hemagglutinin or both. 
Smanjena osjetljivost na zanamivir povezana je s mutacijama koje dovode do promjena aminokiselina u virusnoj neuraminidazi, virusnom hemaglutininu ili oboma.
The serum half-life of zanamivir increases to approximately 12-20 hours in patients with severe renal impairment (creatinine clearance < 30 mL/min). 
Serumski poluvijek zanamivira produljuje se na približno 12 - 20 sati u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min).
Zanamivir is not metabolised, therefore no effect of hepatic impairment is expected. 
Budući da se zanamivir ne metabolizira, ne očekuje se nikakav učinak oštećenja jetrene funkcije.
GM %CV 
GM Raspon GM %CV
Other ingredients are sodium chloride and water for injections. 
Drugi sastojci su natrijev klorid i voda za injekcije.
50 to <80 
50 do < 80
AUC(0-) (g.h/mL) 
AUC(0-∞) (μg.h/ml)
In vitro studies indicate that zanamivir is not an inhibitor or substrate of Breast Cancer Resistant Protein (BCRP), P-glycoprotein, Multidrug And Toxin Extrusion protein (MATE)1, MATE2-K, Organic Anion Transporter (OAT)1, OAT3, Organic Anion Transporting Polypeptide (OATP)1B1, OATP1B3 and Organic Cation Transporter (OCT)2 transporters, nor is it an inhibitor of cytochrome P450 (CYP) enzymes CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4. 
Ispitivanja in vitro ukazuju na to da zanamivir nije inhibitor ni supstrat proteina rezistencije raka dojke (engl. breast cancer resistance protein, BCRP), P-glikoproteina, proteinskih prijenosnika za izlučivanje više lijekova i toksina (engl. multidrug and toxin extrusion protein, MATE) MATE1 i MATE2-K, prijenosnika organskih aniona (engl. organic anion transporter, OAT) OAT1 i OAT3, polipeptidnih prijenosnika organskih aniona (engl. organic anion transporting polypeptide, OATP) OATP1B1 i OATP1B3 i prijenosnika organskih kationa 2 (engl. organic cation transporter, OCT2), kao ni inhibitor enzima citokroma P450 CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 i 3A4 .
The safety profile of Dectova is based primarily on data from a single Phase II and a single Phase III study, with support from Phase I studies, a compassionate use programme, and adverse drug reactions reported for inhaled zanamivir. 
Sigurnosni profil lijeka Dectova prvenstveno se temelji na podacima iz jednog ispitivanja faze II i jednog ispitivanja faze III, a potkrijepljen je podacima iz ispitivanja faze I i programa milosrdne primjene lijeka te nuspojavama prijavljenima kod inhalacijske primjene zanamivira.
Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici iza oznake „EXP“.
In the rat embryofoetal study, there was an increase in the incidence rates of a variety of minor skeletal and visceral alterations, most of which remained within the background rates of the historical occurrence in the strain studied. 
U embriofetalnom ispitivanju na štakorima opažen je porast stopa incidencije raznih manjih koštanih i visceralnih promjena, od kojih je većina ostala unutar osnovne stope dotadašnje učestalosti kod ispitivanog soja.
The median patient age was 57 years and 35% (218/615) of patients were ≥65 years, of which 17% (n=103) were 65 to <75; 14% (n=84) were 75 to <85, and 5% (n=31) were ≥85 years of age. 
bilo u dobi od 65 do < 75 godina, 14% (n=84) u dobi od 75 do < 85 godina, a 5% (n=31) u dobi od ≥ 85 godina.
Influenza Positive Population, N Median TTCR, days 
Populacija pozitivna na gripu (IPP), N Medijan TTCR-a, dani
Hospitalised patients with influenza also have received 300 mg or 600 mg twice daily for 5 to 10 days. 
Hospitalizirani bolesnici s gripom također su primali dozu od 300 mg ili 600 mg dvaput na dan tijekom 5 - 10 dana.
Neuraminidase inhibition occurred at very low zanamivir concentrations in vitro, with median inhibitory (IC50) values of 0.33 nM to 5.77 nM against influenza A and B strains respectively. 
Inhibicija neuraminidaze nastupila je pri vrlo niskim koncentracijama zanamivira in vitro, uz medijan inhibicijske koncentracije (IC50) od 0,33 nM do 5,77 nM protiv sojeva virusa gripe tipa
Zanamivir is not a substrate, inhibitor or inducer of cytochrome P450 isoenzymes nor a substrate or inhibitor of renal and hepatic transporters at clinically relevant concentrations (see section 5.2). 
Zanamivir nije supstrat, inhibitor ni induktor izoenzima citokroma P450, kao ni supstrat ili inhibitor bubrežnih i jetrenih prijenosnika pri klinički relevantnim koncentracijama (vidjeti dio 5.2).
Animal studies indicate no clinically meaningful effects of zanamivir on male or female fertility. 
Ispitivanja na životinjama ne ukazuju na klinički značajne učinke zanamivira na plodnost muškaraca ili žena.
15 to <30 
15 do < 30
Solution for infusion A clear, colourless solution for infusion. 
Otopina za infuziju Bistra, bezbojna otopina za infuziju.
Initial Dose Maintenance Dose Maintenance Dose Schedule 
Početna doza Doza održavanja Raspored primjene doze održavanja
Zanamivir is not an inducer of CYP1A2 and 2B6 and, although induction of CYP3A4 in vitro was observed at 50-fold higher than the clinically relevant concentrations, no interaction with CYP3A4 substrates is expected based on physiologically based pharmacokinetic modelling. 
Zanamivir nije induktor enzima CYP1A2 ni CYP2B6 te iako je pri koncentracijama 50 puta višima od klinički relevantnih opažena indukcija CYP3A4 in vitro, na temelju fiziološkog farmakokinetičkog modeliranja ne očekuje se interakcija sa supstratima CYP3A4.
Results from a rat peri- and postnatal study showed no clinically meaningful impairment of offspring development. 
Rezultati perinatalnog i postnatalnog ispitivanja na štakorima nisu pokazali klinički značajne štetne učinke na razvoj mladunčadi.
It is unknown whether zanamivir is excreted in human milk. 
Nije poznato izlučuje li se zanamivir u majčino mlijeko.
Anaphylactic reactions and serious skin reactions (including erythema multiforme, toxic epidermal necrolysis and Stevens-Johnson syndrome) have been reported with zanamivir (see section 4.8). 
Kod primjene zanamivira prijavljene su anafilaktičke reakcije i ozbiljne kožne reakcije (uključujući multiformni eritem, toksičnu epidermalnu nekrolizu i Stevens-Johnsonov sindrom) (vidjeti dio 4.8).
Adverse reactions are listed by MedDRA system organ class. 
Nuspojave su navedene prema MedDRA klasifikaciji organskih sustava.
Table 1: Weight-based dose regimen by age for infants, children and adolescents with normal renal function 
Tablica 1: Režim doziranja na temelju tjelesne težine prema dobi za dojenčad, djecu i adolescente s normalnom bubrežnom funkcijom Raspon dobi
In rats, zanamivir has been shown to be secreted in low amounts into milk. 
U štakora se zanamivir izlučivao u mlijeko u malim količinama.
This medicinal product contains 70.8 mg sodium per vial, equivalent to 3.54% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
Ovaj lijek sadrži 70,8 mg natrija po bočici, što odgovara 3,54% maksimalnog dnevnog unosa od 2 g natrija prema preporuci Svjetske zdravstvene organizacije (SZO) za odraslu osobu.
Do not use Dectova: 
Nemojte primiti lijek Dectova:
Zanamivir is eliminated unchanged in urine by glomerular filtration. 
Zanamivir se glomerularnom filtracijom eliminira kroz mokraću u nepromijenjenom obliku.
30 to <50 
30 do < 50
The study did not meet its pre-specified primary objective of demonstrating superiority of 600 mg zanamivir to oral oseltamivir or to 300 mg zanamivir in TTCR. 
Ispitivanje nije postiglo unaprijed specificiran primarni cilj - dokazivanje superiornosti zanamivira u dozi od 600 mg u odnosu na oralni oseltamivir ili zanamivir u dozi od 300 mg s obzirom na TTCR.
The frequency of adverse reactions is based on the number of reports in the adult population receiving zanamivir 600 mg twice daily intravenously in the Phase II and Phase III studies. 
Učestalost nuspojava temelji se na broju slučajeva prijavljenih u odrasloj populaciji koja je primala zanamivir u intravenskoj dozi od 600 mg dvaput na dan u ispitivanjima faze II i faze III.
A number of neuraminidase amino acid substitutions that arise during oseltamivir or peramivir treatment result in reduced susceptibility to zanamivir. 
Velik broj supstitucija aminokiselina u neuraminidazi koje nastaju tijekom liječenja oseltamivirom ili peramivirom dovodi do smanjene osjetljivosti na zanamivir.
years mg/kg years mg/kg years mg years mg %CV = percent coefficient of variation, GM = Geometric Mean, NA = Not available 
mg % CV = postotni koeficijent varijacije, GM = geometrijska srednja vrijednost, ND = nije dostupno
The serum pharmacokinetics of zanamivir administered intravenously have been studied in healthy volunteers receiving single escalating doses from 1 to 1200 mg and repeated doses of 600 mg twice daily for 5 days. 
Serumska farmakokinetika intravenski primijenjenog zanamivira ispitivala se u zdravih dobrovoljaca koji su primali pojedinačne doze od 1 do 1200 mg, koje su se postupno povećavale, te ponovljene doze od 600 mg dvaput na dan tijekom 5 dana.
When and how Dectova is given Dectova should be given as soon as possible, usually within 6 days of the symptoms of flu appearing. 
Lijek Dectova treba primijeniti što je prije moguće, obično unutar 6 dana od pojave simptoma gripe.
Dectova is a clear, colourless solution for infusion containing 200 mg zanamivir (as hydrate) in 20 mL. 
Dectova je bistra, bezbojna otopina za infuziju koja sadrži 200 mg zanamivira (u obliku hidrata) u
The most commonly reported adverse reactions considered possibly or probably related to Dectova are alanine aminotransferase increased (2%), aspartate aminotransferase increased (1%), hepatocellular injury (1%), diarrhoea (1%) and rash (1%). 
Dectova su povišene vrijednosti alanin aminotransferaze (2%), povišene vrijednosti aspartat aminotransferaze (1%), hepatocelularno oštećenje (1%), proljev (1%) i osip (1%).
The clinical impact of substitutions associated with reduced susceptibility to zanamivir and other neuraminidase inhibitors is variable and may be strain-dependent. 
Klinički utjecaj supstitucija povezanih sa smanjenom osjetljivošću na zanamivir i druge inhibitore neuraminidaze varijabilan je i mogao bi ovisiti o soju.
Treatment emergent resistance is rare with zanamivir (see section 5.1). 
Kod liječenja zanamivirom rijetko se razvija rezistencija (vidjeti dio 5.1).
Dectova has not been studied in patients with end-stage renal disease. 
Dectova se nije ispitivala u bolesnika u terminalnoj fazi bubrežne bolesti.
Serious skin or allergic reactions may occur after Dectova is given. 
Ozbiljne kožne ili alergijske reakcije Nakon primjene lijeka Dectova mogu se javiti ozbiljne kožne ili alergijske reakcije.
Following twice-daily administration of zanamivir solution for infusion, pulmonary epithelial lining fluid concentrations were 60 - 65 % of the serum concentrations at the corresponding sampling time 12 hours after dosing. 
Nakon primjene zanamivira u obliku otopine za infuziju dvaput na dan, njegove koncentracije u sekretu plućnog epitela iznosile su 60 - 65% koncentracija u serumu u odgovarajućem trenutku uzorkovanja 12 sati nakon primjene.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2ºC to 8ºC, unless dilution has taken place in controlled and validated aseptic conditions. 
Pripremljeni se lijek ne smije čuvati dulje od 24 sata na temperaturi od 2°C do 8ºC, osim ako je razrjeđivanje provedeno u kontroliranim i validiranim aseptičnim uvjetima.
Reproductive studies performed in rats and rabbits indicated that placental transfer of zanamivir occurs and there was no evidence of teratogenicity. 
Ispitivanja učinaka na reprodukciju provedena na štakorima i kunićima ukazala su da zanamivir prolazi kroz posteljicu, ali nije bilo dokaza teratogenosti.
Dose N Cmax (g/mL) 
Doza N Cmax (μg/ml)
Side effects where it is not known how likely they are to happen There isn't enough information to estimate how likely these side effects are: 
Nema dovoljno informacija da bi se procijenilo koliko su vjerojatne sljedeće nuspojave:
Selection of influenza resistant viruses is more likely to occur following treatment with antiviral medicinal products in immunocompromised patients, including treatment with Dectova; it is, therefore, important to monitor for resistance and consider switching to alternative therapies where appropriate. 
vjerojatnija u imunokompromitiranih bolesnika, važno je pratiti bolesnike zbog mogućeg razvoja rezistencije i razmotriti prelazak na neku drugu terapiju kad je to moguće.